Effect of Rowachol on Prevention of Postcholecystectomy Syndrome
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
Postcholecystectomy syndrome (PCS) includes a heterogeneous group of diseases, usually
manifested by the presence of abdominal symptoms following gallbladder removal. The
pathogenesis of PCS has not been identified; therefore there is no consensus of medical
treatment on PCS. The Action of Rowachol are to inhibit hepatic 3-hydroxy-3-methylglutaric
acid(HMG)-coenzyme A(CoA) reductase, to inhibits cholesterol nucleation in bile from patients
with cholesterol gallstones, and to promote biliary lipid secretion.
The purpose of this study is to determine whether Rowachol is useful in the prevention of PCS
and symptoms change after laparoscopic cholecystectomy